398 related articles for article (PubMed ID: 11987029)
1. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
3. Products of advanced glycation in patients with type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Pokupec R; Turk N; Stavljenić-Rukavina A
Ann Clin Biochem; 2003 Sep; 40(Pt 5):552-9. PubMed ID: 14503994
[TBL] [Abstract][Full Text] [Related]
4. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus.
Lopez LR; Hurley BL; Simpson DF; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():97-103. PubMed ID: 16126948
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
[TBL] [Abstract][Full Text] [Related]
6. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus.
Leinonen JS; Rantalaiho V; Laippala P; Wirta O; Pasternack A; Alho H; Jaakkola O; Ylä-Herttuala S; Koivula T; Lehtimäki T
Free Radic Res; 1998 Aug; 29(2):137-41. PubMed ID: 9790515
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
8. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.
Atchley DH; Lopes-Virella MF; Zheng D; Kenny D; Virella G
Diabetologia; 2002 Nov; 45(11):1562-71. PubMed ID: 12436340
[TBL] [Abstract][Full Text] [Related]
9. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
Bakalova RA; Hadzhimitova V; Ribarov S
Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
[TBL] [Abstract][Full Text] [Related]
10. Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease.
Granér M; Kahri J; Nakano T; Sarna SJ; Nieminen MS; Syvänne M; Taskinen MR
Eur J Clin Invest; 2006 Nov; 36(11):764-70. PubMed ID: 17032343
[TBL] [Abstract][Full Text] [Related]
11. [Antibodies against low density oxidized lipoproteins in type 2 diabetics].
Malícková K; Skrha J; Janatková I; Vanková Z; Fucíková T
Epidemiol Mikrobiol Imunol; 2004 Aug; 53(3):131-5. PubMed ID: 15524272
[TBL] [Abstract][Full Text] [Related]
12. [Lipoprotein (a) and ischemic heart diseases in patients with type 2 diabetes].
Ben Hamda K; Masmoudi AS; Mandhouj O; Hammami S; Attia N; Smaoui M; Zidi MA; Nabli N; Chaaba R; Mahjoub S; Ben Farhat M; Hammami M
Arch Inst Pasteur Tunis; 2002; 79(1-4):27-33. PubMed ID: 15072242
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
14. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
Turk Z; Mrzljak V; Turk N; Metelko Z
Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
[TBL] [Abstract][Full Text] [Related]
15. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease.
Andican G; Seven A; Uncu M; Cantaşdemir M; Numan F; Burçak G
Scand J Clin Lab Invest; 2008; 68(6):473-8. PubMed ID: 18609113
[TBL] [Abstract][Full Text] [Related]
16. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
Girona J; Manzanares JM; Marimón F; Cabré A; Heras M; Guardiola M; Ribalta J; Masana L
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C.
Antoniades C; Tousoulis D; Tountas C; Tentolouris C; Toutouza M; Vasiliadou C; Tsioufis C; Toutouzas P; Stefanadis C
Diabet Med; 2004 Jun; 21(6):552-8. PubMed ID: 15154938
[TBL] [Abstract][Full Text] [Related]
18. Lipid profile in patients with coronary artery disease.
Haddad FH; Omari AA; Shamailah QM; Malkawi OM; Shehab AI; Mudabber HK; Shubaki MK
Saudi Med J; 2002 Sep; 23(9):1054-8. PubMed ID: 12370711
[TBL] [Abstract][Full Text] [Related]
19. Differences in human antioxidized LDL autoantibodies in patients with stable and unstable angina.
Fernandes JL; Orford JL; Garcia C; Coelho OR; Gidlund M; Blotta MH
J Autoimmun; 2004 Dec; 23(4):345-52. PubMed ID: 15571928
[TBL] [Abstract][Full Text] [Related]
20. Effects of coronary artery disease and percutaneous intervention on the cardiac metabolism of nonesterified fatty acids and insulin: Implications of diabetes mellitus.
Jaumdally RJ; Lip GY; Patel JV; MacFadyen RJ; Varma C
J Intern Med; 2009 Jun; 265(6):689-97. PubMed ID: 19226374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
